BioFlo

Evolve to BioFlo Ports with Endexo Technology

96%
LESS THROMBUS ACCUMULATION
COMPARED TO BARD POWERPORT WITH CHRONOFLEX CATHETER
(based on platelet count)[1,2]

angiodynamics

Proven to Reduce Thrombus Accumulation, In Vitro[1]

The BioFlo* Port is the first implantable port with Endexo* Technology, providing a catheter material more resistant to the in-vitro accumulation of blood components compared to non-coated port catheters (based on platelet count).[1,2]

Endexo Technology is a permanent and non-eluting polymer that is "blended" into the polyurethane from which the catheter is made. It is present throughout the catheter including the extraluminal, intraluminal and cut catheter surface of the tip. Endexo Technology remains present for the life of the catheter and provides a catheter material more resistant to thrombus accumulation.[1]



SEM (Scanning Electron Microscopy) Images

BioFlo Port at 15X magnification
Catheter has no visible thrombus, fibrin sheath, or clot.



Bard PowerPort* with ChronoFlex* catheter at 15X magnification
Catheter has significant thrombus, fibrin sheath, or clot.



Easily Identify Critical Information

- Radiopaque "CT" lettering confirms if port is power injectable or flipped
- Patient reminder band, ID card, key tag and record sticker provide added verification that the port is power injectable

Titanium Port

Plastic Port



BioFlo Ports—Combining the Power of PASV with CT Rated Ports

The Power of PASV

VALVE PASV TECHNOLOGY

The PASV® Valve Technology design automatically resists backflow, reducing blood reflux that could lead to catheter-related complications.

BioFlo Power-Injectable Ports are indicated up to 5mL/sec and 300 psi and are MRI-conditional—3 Tesla.



saline ONLY OPTION

Plastic Port with PASV Valve Technology

Decreased Costs[3]

39%

REDUCTION

NET MAINTENANCE
COST PER PORT



Reduced Complications[4]

47% REDUCTION IN INADEQUATE BLOOD DRAW

Inability to draw blood—11% Non-valved, 5.8% PASV Valve Technology

51% REDUCTION IN TROUBLESHOOTING TIME

Nursing time—1,545 minutes Non-valved, 750 minutes PASV Valve Technology

35% REDUCTION IN TPA USAGE

Rate of occlusion—6.7% Non-Valved, 4.4% PASV Valve Technology

PASV Valve Technology is designed to:

Open with minimal pressure and automatically close after infusion



Open for sampling and automatically close to resist pressure fluctuations that may cause blood reflux



Remain closed during normal increases in central venous pressure to prevent blood reflux in the catheter tip



BioFlo Port—Ordering Information

UPN	CATHETER SIZE	SUTURE HOLE	VALVED OR NON VALVED
PLASTIC DUAL PORTS			
H965440270	8F	Non-Filled	Non-Valved
H965440280	8F	Filled	Non-Valved
PLASTIC SINGLE PORTS			
H965440110	6F	Non-Filled	Non-Valved
H965440120	6F	Filled	Non-Valved
H965440130	8F	Non-Filled	Non-Valved
H965440140	8F	Filled	Non-Valved
H965440190	6F	Non-Filled	Valved
H965440200	6F	Filled	Valved
H965440210	8F	Non-Filled	Valved
H965440220	8F	Filled	Valved
TITANIUM SINGLE PORTS			
H965440150	6F	Non-Filled	Non-Valved
H965440170	8F	Non-Filled	Non-Valved
H965440230	6F	Non-Filled	Valved
H965440250	8F	Non-Filled	Valved

BIOFLO PORT KITS INCLUDE:
Port; Attachable single lumen catheter; Snaplocks (1); 18G Introducer needle; 0.038x 50cm J-guidewire; Valved introducer sheath; Metal tunneler; 17G Blunt needle; 22G Huber Needles: Straight (1), 90° (1); 12 mL Syringes: Slip (1), Luer (1); Safety infusion set (tandem); DFU & Patient Packet

1. The reduction in thrombus accumulation (based on platelet count), is supported by acute in-vitro testing. Pre-clinical in-vitro evaluations do not necessarily predict clinical performance with respect to thrombus formation.
2. Based on benchtop testing performed up to two hours using bovine blood, which may not be indicative of clinical results. Data on file.
3. Failure to achieve blood draw: non-valved=$480, valved=$303; $177 net savings per port. General maintenance costs: non-valved=$195, valved=$109; $86 net savings per port. Cost information based on data from 2004
4. Carlo JT, Lamont JP, McCarty TM, Livingston S, Kuhn JA. A Prospective Randomized Trial Demonstrating Valved Implantable Ports Have Fewer Complications and Lower Overall Cost than Non-valved Implantable Ports. Am J Surg 2004;188:722-727. (Clinical data based on Vaxcel with PASV Valve Technology Port.)

Consult your AngioDynamics representative for country specific product availability.

IMPORTANT RISK INFORMATION

INTENDED USE/INDICATIONS FOR USE: The BioFlo Port with ENDEXO Technology and the BioFlo Port with ENDEXO and PASV Valve Technology are indicated for patients who require long-term access to the central venous system for administration of fluids including but not limited to hydration fluids, chemotherapy, analgesics, nutritional therapy and blood products. The device is also indicated for blood specimen withdrawal.

When used with a power injectable needle, the BioFlo Ports are indicated for power injection of contrast media. The maximum recommended infusion rate is 5 mL/sec with a 19G or 20G non-coring power injectable needle or 2 mL/sec with a 22G non-coring power injectable needle

CONTRAINDICATIONS
- Catheter insertion in the subclavian vein medial to the border of the first rib, an area which is associated with higher rates for pinch-off.
- Presence of infection, bacteremia, septicemia or peritonitis.
- Past irradiation of prospective insertion site.
- Previous episodes of venous thrombosis or vascular surgical procedures at the prospective placement site.
- Local tissue factors to prevent proper device stabilization and/or access.
- Hypercoagulopathy unless considerations are made to place the patient on anticoagulation therapy.
- Presence or suspicion of allergic reaction to materials contained in this device.
- Body size is insufficient to accommodate size of the port or the catheter.
- Demonstrated intolerance for an implanted device.

Refer to package insert provided with the product for complete Instructions for Use, Contraindications, Possible Complications, Warnings and Precautions prior to using this product.

CAUTION: Federal Law (USA) restricts this device for sale by or on the order of a physician.

angiodynamics

USA > 14 Plaza Drive, Latham, NY 12110 > tel: 800-772-6446 or 518-798-1215 > fax: 518-798-1360
International > Haaksbergweg 75 (Margriettoren), 1101 BR, Amsterdam Z-O > The Netherlands
tel: +31 (0)20 753 2949 > fax: +31 (0)20 753 2939

www.angiodynamics.com

*AngioDynamics, the AngioDynamics logo, BioFlo, the BioFlo logo and PASV are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or a subsidiary. Endexo is a trademark and/or registered trademark of Interface Biologics, Inc. PowerPort and ChronoFlex are trademarks of C.R.Bard, Inc. © 2017 AngioDynamics, Inc. ANGB 023 GL Rev 04 02/17